T2DM

MediciNova Announces Two Abstracts regarding MN-001 (tipelukast) and MN-002 Accepted for Presentation at the 92nd EAS 2024 Congress, the Annual Meeting of the European Atherosclerosis Society

Retrieved on: 
Wednesday, March 20, 2024
Congress, Juntendo University, Dyslipidemia, Patient, SAFETY, Research, Code, MD, Abstract, Type 2 diabetes, HTG, Tokyo Stock Exchange, EAS, Lipid metabolism, NAFLD, T2DM, Pharmaceutical industry

Presentation details will be disseminated as they become available.

Key Points: 
  • Presentation details will be disseminated as they become available.
  • Ph.D., M.P.H., Chief Medical Officer, MediciNova, Inc., commented, “We are very pleased that the two presentations were accepted at the EAS 2024 Congress.
  • One presentation is regarding the objectives and design of the ongoing Phase 2 clinical trial enrolling patients with Type 2 diabetes, dyslipidemia, and NAFLD.
  • The other presentation is regarding the mechanism of action of MN-001/MN-002 in lipid metabolism, particularly the effects on cholesterol efflux capacity.

HeartSciences’ Announces Peer-Reviewed Publication Evaluating Use of MyoVista® Technology to Detect Asymptomatic Left Ventricular Dysfunction in Patients with Type 2 Diabetes

Retrieved on: 
Tuesday, March 12, 2024
Diabetes, ARIC, HSCS, Cardiovascular disease, Algorithm, Learning, Risk, Intelligence, Patient, Atherosclerosis, HF, Death, Type 2 diabetes, Type, Use, T2DM, Cardiovascular Diabetology, Medicine, Medical device

Recent guidelines propose N-terminal pro-B-type natriuretic peptide (blood test for NT-proBNP protein marker) for recognition of asymptomatic left ventricular (LV) dysfunction (Stage B Heart Failure, SBHF) in type 2 diabetes (T2DM) patients.

Key Points: 
  • Recent guidelines propose N-terminal pro-B-type natriuretic peptide (blood test for NT-proBNP protein marker) for recognition of asymptomatic left ventricular (LV) dysfunction (Stage B Heart Failure, SBHF) in type 2 diabetes (T2DM) patients.
  • Accordingly, the study sought to evaluate whether an AI-ECG model based on MyoVista® wavECG™ features was superior to NT-proBNP, as well as a conventional screening tool—the Atherosclerosis Risk in Communities (ARIC) HF risk score, in SBHF screening among patients with T2DM.
  • This independent study provides evidence of the clinical and diagnostic capabilities of AI-ECG, and specifically our MyoVista wavECG technology, to potentially advance current standards of care for heart screening in diabetic patients.” said Andrew Simpson, Chief Executive Officer of HeartSciences.
  • “Globally cardiovascular disease accounts for approximately one-third of all annual deaths and AI-ECG is set to change medicine by providing the opportunity to detect heart disease earlier and more effectively, not only for diabetic patients, but also for a significant number of at-risk patients.

NeuroBo Pharmaceuticals Receives Safety Review Committee Approval to Continue With Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH

Retrieved on: 
Wednesday, March 13, 2024
SRC, Week, Cirrhosis, ALT, Disease, Safety, Part, Patient, GPR119, Aes, Șaeș, Alanine transaminase, MASH, Clinical trial, Type, Liver disease, T2DM, Triglyceride, Pharmaceutical industry

CAMBRIDGE, Mass., March 13, 2024 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced receipt of Safety Review Committee (SRC) approval, recommending that the two-part Phase 2a trial of DA-1241, a novel G-Protein-Coupled Receptor 119 (GPR119) agonist for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), continue without modification following a blinded safety review of the first six months of study conduct. The Phase 2a clinical trial is designed to evaluate the efficacy and safety of DA-1241, for the treatment of MASH. The company anticipates a full data readout from the trial in the second half of 2024.

Key Points: 
  • The Phase 2a clinical trial is designed to evaluate the efficacy and safety of DA-1241, for the treatment of MASH.
  • The company anticipates a full data readout from the trial in the second half of 2024.
  • Each of the two-parts of the Phase 2a trial of DA-1241 are designed to be 16-week, multicenter, randomized, double-blind, placebo-controlled, parallel clinical studies to evaluate the efficacy and safety of DA-1241 in subjects with presumed MASH.
  • Subjects will be randomized in a 1:2:1 ratio into 3 treatment groups: DA-1241 50 mg, DA-1241 100 mg, or placebo.

Lexicon Pharmaceuticals Provides Business and Pipeline Update at 42nd Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Monday, January 8, 2024
Lithium, UGT, Risk, Digoxin, Shanda, Hypotension, FDA, SGLT1, Type 2 diabetes, Acute kidney injury, Congress, Pyelonephritis, Conference, Fever, Ketoacidosis, Pregabalin, Pregnancy, Pain, Assessment, Gabapentin, Tenderness, New Drug Application, Amber Grid, HCM, Common, SGLT2, PROGRESS, Hypertrophic cardiomyopathy, Diabetes, Kidney, Heart failure, Dialysis, History, Patient, Prescription, Type, Neuropathic pain, Webcast, Insulin, T2DM, EGFR, Erythema, T1DM, Hypoglycemia, Partnership, Contraindication, Diarrhea, NDA, Incidence, Swelling, Urinary tract infection, Hospital, Chronic kidney disease, Internationalized domain name, Metabolic acidosis, Creatinine, Growth, Lactation, Pharmaceutical industry

THE WOODLANDS, Texas, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company with a mission of pioneering medicines that transform patients’ lives, today announced a business and pipeline update at the 42nd Annual J.P. Morgan Healthcare Conference taking place January 8-12, 2024.

Key Points: 
  • THE WOODLANDS, Texas, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company with a mission of pioneering medicines that transform patients’ lives, today announced a business and pipeline update at the 42nd Annual J.P. Morgan Healthcare Conference taking place January 8-12, 2024.
  • “Lexicon achieved major advancements in 2023 in its business and pipeline of pharmaceutical innovations,” said Lonnel Coats, chief executive officer and director of Lexicon.
  • The company will also focus on ensuring a strong ongoing awareness of INPEFA in the medical community through medical publications and congress presence.
  • Company to Present at J.P. Morgan Healthcare Conference Thursday, January 11, 2024 at 10:30am PST (1:30pm ET)
    Lonnel Coats, Lexicon’s chief executive officer, will make a company presentation.

Lexicon Enrolls First Patient in Phase 2b Progress Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP)

Retrieved on: 
Thursday, November 30, 2023
T1DM, Food, FDA, AAK1, Type, Lexicon Pharmaceuticals, Patient, Dose-ranging study, Neuropathic pain, Extension, Trial of the century, Diagnosis, PROGRESS, Safety, T2DM, Fast Track, Pharmaceutical industry

THE WOODLANDS, Texas, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that it has enrolled the first patient in PROGRESS (A Phase 2b, Dose-ranging, Randomized, Double-blind, PlacebO-controlled, Parallel-GRoup, MulticEnter Study with an Open-label Extension in PatientS with Diabetic Peripheral Neuropathic Pain) studying LX9211, a potent, orally-delivered, selective, investigational small molecule inhibitor of adaptor-associated kinase 1 (AAK1).

Key Points: 
  • PROGRESS will enroll adult patients with a diagnosis of type 1 diabetes mellitus (T1DM) or type 2 diabetes mellitus (T2DM) with moderate to severe DPNP.
  • The primary endpoint of PROGRESS is a reduction of Average Daily Pain Score (ADPS), consistent with the primary endpoint achieved in the successful RELIEF-DPN-1 Phase 2a proof-of-concept study and, informed by regulatory feedback, the primary endpoint planned for Phase 3 studies of LX9211 in DPNP.
  • The placebo-controlled treatment period of PROGRESS is intended to identify the optimal dosing for Phase 3 studies.
  • The open-label extension is expected to run in parallel with planned next-stage Phase 3 studies, supporting long-term safety requirements for regulatory approval.

Structure Therapeutics Reports Third Quarter 2023 Financial Results and Recent Highlights

Retrieved on: 
Tuesday, November 14, 2023
Structure, Safety, SAN, D, Investment, Research, Obesity, Therapy, Growth, GPCR, Weight loss, Pharmaceutical industry, T2DM

SAN FRANCISCO, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, today reported financial results for the third quarter ended September 30, 2023, and highlighted recent corporate achievements.

Key Points: 
  • “Our recent Phase 1b data support the potential of GSBR-1290 as a promising, differentiated oral GLP-1 receptor agonist with once-daily dosing,” said Raymond Stevens, Ph.D., Founder and CEO of Structure Therapeutics.
  • GSBR-1290 demonstrated significant weight loss of up to 4.9% (placebo-adjusted) supporting once-daily dosing, and an encouraging safety profile with no adverse event-related discontinuations.
  • In preparation for these studies, Structure has initiated a formulation bridging study to evaluate a tablet formulation of GSBR-1290.
  • R&D Expenses: Research and development expenses were $17.5 million for the quarter ended September 30, 2023, as compared to $9.2 million for the same period in 2022.

Alnylam Highlights Significant Progress with Platform Innovation and Clinical Pipeline at R&D Day

Retrieved on: 
Wednesday, December 13, 2023
Biotechnology, Health, Genetics, Pharmaceutical, Clinical Trials, CNS, Hypertension, Cerebral amyloid angiopathy, Hepatocellular carcinoma, Gene, ALN, Cardiomyopathy, RNA interference, IND, Tissue, Liver, Sanofi, Amyloidosis, Gene silencing, Overweight, KHK, Patient, FGF21, CAA, Part, Obesity, T2DM, Neoplasm, Investigational New Drug, Therapy, LNP, Development, Shanda, Growth, HCC, Central nervous system, Type, TTR, Immunotherapy, Polyneuropathy, Haemophilia, Medication, Biology, Coagulopathy, Traffic barrier, Adipose tissue, Vaccine, Medical device, Pharmaceutical industry, Video game, Alnylam Pharmaceuticals, Capella, ATTR

We expect our track record of strong pipeline and commercial execution to continue through the end of 2025 and beyond,” said Akshay Vaishnaw, M.D., Ph.D., Chief Innovation Officer of Alnylam.

Key Points: 
  • We expect our track record of strong pipeline and commercial execution to continue through the end of 2025 and beyond,” said Akshay Vaishnaw, M.D., Ph.D., Chief Innovation Officer of Alnylam.
  • In addition, Alnylam will share an update on delivery advances driving ALN-BCAT, which will soon begin clinical testing in patients with hepatocellular carcinoma (HCC).
  • A peak mean TTR reduction of 97% was achieved at Day 29 and a mean TTR reduction of 93% was sustained at Day 180.
  • The Company’s R&D Day event will be held today, Wednesday, Dec. 13, from 8:30 a.m. to 12:45 p.m.

HighTide Therapeutics Inc. is Invited to Present at the 7th Edition of the Future Investment Initiative (FII): The New Compass, in Riyadh, Saudi Arabia

Retrieved on: 
Friday, October 27, 2023
Berberine, Ageing, Attention, Future Investment Initiative Institute, AMPK, Conference, Research, Type 2 diabetes, FII, Ursodeoxycholic acid, NME, Quality of life, HighTide, NASH, Insulin resistance, AI, Therapy, Patient, T2DM, Fatty liver disease, Pharmaceutical industry

The rising burden of aging-related diseases has become an urgent global health challenge that requires immediate attention.

Key Points: 
  • The rising burden of aging-related diseases has become an urgent global health challenge that requires immediate attention.
  • Recent advances in anti-aging research and big data empower a more holistic approach to understanding and reversing human aging with evidence suggests that slowing down aging can substantially improve quality of life.
  • The FII Conference, hosted by the Future Investment Initiative (FII) Institute, has been held for seven consecutive years and has developed into one of the most important economic and investment forums in the Middle East.
  • This year's conference (FII7) was attended exclusively by FII Institute members, strategic partners, decision-makers, and international leaders, and is expected to draw 5,000 delegates attending sessions covering a wide variety of issues with global impact.

Structure Therapeutics Reports Second Quarter 2023 Financial Results and Recent Highlights

Retrieved on: 
Thursday, August 10, 2023
PK, BIO, Obesity, Therapy, ATS, LPAR1, Pharmacokinetics, Ted, T2DM, Trial of the century, Type, GPCR, American Thoracic Society, International Conference on Emerging Infectious Diseases, Investment, Biotechnology Innovation Organization, Annual general meeting, Overweight, MAD, Research, American Diabetes Association, ADA, Conference, Safety, D, Pharmaceutical industry, Cryptocurrency

SAN FRANCISCO, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, today reported financial results for the second quarter June 30, 2023, and highlighted recent corporate achievements.

Key Points: 
  • Completed enrollment in 12-week Phase 2a study of oral GLP-1 receptor agonist, GSBR-1290
    SAN FRANCISCO, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, today reported financial results for the second quarter June 30, 2023, and highlighted recent corporate achievements.
  • Topline data are expected to be announced in latter half of fourth quarter 2023.
  • Structure Therapeutics presented data from the Phase 1 single ascending dose clinical study and preclinical data of GSBR-1290 at the 2023 American Diabetes Association (ADA) Annual Meeting in June 2023.
  • R&D Expenses: Research and development expenses were $19.4 million for the quarter ended June 30, 2023, as compared to $10.2 million for the same period in 2022.

ReShape Lifesciences® Presents Data on its Proprietary Diabetes Bloc-Stim Neuromodulation™ Device at the ASMBS 2023 Annual Meeting

Retrieved on: 
Wednesday, June 28, 2023
Insulin, Diet, Weight loss, Pancreas, OGTT, Diabetes, T2DM, Organization, Metabolism, Alloxan, Blood, Annual general meeting, Liver, ASMBS, Research, Pig, Society, NIH, Bariatric surgery, AU, Pharmaceutical industry, AUC, Zucker

“Type 2 Diabetes Mellitus (T2DM) remains challenging to effectively treat, despite medication, surgery and diet,” stated Jonathan Waataja, Ph.D. Director of Research at ReShape Lifesciences.

Key Points: 
  • “Type 2 Diabetes Mellitus (T2DM) remains challenging to effectively treat, despite medication, surgery and diet,” stated Jonathan Waataja, Ph.D. Director of Research at ReShape Lifesciences.
  • “ReShape’s DBSN™ device selectively modulates vagal block and stimulation to the liver and pancreas to manage blood glucose.
  • Increased glycemic control has been demonstrated in a Zucker rat model of T2DM as well as in an alloxan treated swine model of T2DM.
  • There was an apparent, but non-significant, increase in baseline insulin following stimulation and block experiments (pre-experiments =10.7±2.6 µIU/mL, post-experiments=15.4±2.9 µIU/mL, p=0.28).